You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

breast cancer; pyrotinib; trastuzumab; pertuzumab

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Active, not recruiting
  • Breast Cancer
  • Pyrotinib Plus Trastuzumab
  • Pertuzumab Plus Trastuzumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 5, 2022

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital of China Medical University
Dec 2, 2022

HER2-positive Breast Cancer Trial in Shenyang (ARX788, Pyrotinib maleate, Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jun 21, 2022

Breast Cancer Invasive Trial in Shanghai (Pyrotinib, Trastuzumab, Pertuzumab)

Active, not recruiting
  • Breast Cancer Invasive
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022

Breast Cancer Trial in Nanjing (Neoadjuvant therapy: TCbHPy, Neoadjuvant therapy: TCbHP)

Not yet recruiting
  • Breast Cancer
  • Neoadjuvant therapy: TCbHPy
  • Neoadjuvant therapy: TCbHP
  • Nanjing, China
    the First Affiliated Hospital of Nanjing Medical University
Jul 4, 2022

Breast Tumors Trial in Shenyang (Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting

Recruiting
  • Breast Neoplasms
  • Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 30, 2022

Breast Cancer, Adjuvant Therapy Trial in Fuzhou (Pyrotinib+Trastuzumab+Capecitabine, Trastuzumab+Pertuzumab/Trastuzumab)

Recruiting
  • Breast Cancer
  • Adjuvant Therapy
  • Fuzhou, Fujian, China
    Fujian Medical University Union Hospital
Mar 14, 2022

Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab)

Not yet recruiting
  • Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jul 13, 2021

Breast Cancer Trial (Pyrotinib Maleate Tablets)

Not yet recruiting
  • Breast Cancer
  • Pyrotinib Maleate Tablets
  • (no location specified)
Jan 4, 2022

HER2+ Early or Locally Advanced Breast Cancer Trial (pyrotinib + trastuzumab + nab-paclitaxel, pertuzumab + trastuzumab +

Not yet recruiting
  • HER2+ Early or Locally Advanced Breast Cancer
  • pyrotinib + trastuzumab + nab-paclitaxel
  • pertuzumab + trastuzumab + nab-paclitaxel
  • (no location specified)
May 19, 2021

HER2+ Breast Cancer Trial in Xi'an (Trastuzumab, Pertuzumab, Nab paclitaxel)

Recruiting
  • HER2+ Breast Cancer
  • Xi'an, Shaanxi, China
  • +1 more
Jun 20, 2022

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Breast Cancer Trial in Nanjing (Pyrotinib, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    the First Affiliated Hospital of Nanjing Medical University
Jun 2, 2021

PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Recruiting
  • Breast Cancer
  • Docetaxel combined with Trastuzumab±Pertuzumab
  • T-DM1 or Capecitabine combined with Pyrotinib regimen.
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 19, 2022

Breast Cancer Trial in Chengdu (Pyrotinib combined with albumin-bound paclitaxel and trastuzumab)

Recruiting
  • Breast Cancer
  • Pyrotinib combined with albumin-bound paclitaxel and trastuzumab
  • Chengdu, Chengdu, Sichuan, China, China
    West China Hospital, Sichuan University
Oct 7, 2022

HER2-positive Breast Cancer, Brain Metastases Trial in Beijing, Guangzhou, Hangzhou (Trastuzumab, Taxanes, Pertuzumab)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Brain Metastases
  • Beijing, Beijing, China
  • +2 more
May 28, 2021

Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

Not yet recruiting
  • Breast Cancer Female
  • Pyrotinib and Trastuzumab
  • (no location specified)
Sep 11, 2023

Breast Cancer Trial (Pyrotinib, Trastuzumab, Paclitaxel)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Apr 22, 2023

HER2-PositiveRecurrent or Metastatic Breast Cancer Trial (SHR-A1811 Injection, SHR-A1811 Injection ; Pertuzumab Injection,

Not yet recruiting
  • HER2-PositiveRecurrent or Metastatic Breast Cancer
  • SHR-A1811 Injection
  • +2 more
  • (no location specified)
Sep 21, 2023

Breast Cancer Trial in Yantai (pyrotinib combined with trastuzumab, dalpiciclib and letrozole)

Recruiting
  • Breast Cancer
  • pyrotinib combined with trastuzumab, dalpiciclib and letrozole
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Mar 23, 2023

Breast Cancer, Neoadjuvant Trial in Wuhan (pyrotinib,Trastuzumab,carboplatin,Albumin paclitaxel)

Recruiting
  • Breast Cancer
  • Neoadjuvant
  • pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
  • Wuhan, Hubei, China
  • +1 more
Aug 18, 2023

HER2-positive Breast Cancer Trial in Nanjing (Pyrotinib)

Recruiting
  • HER2-positive Breast Cancer
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 26, 2023

Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic

Completed
  • Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Apr 20, 2023

    Breast Cancer Trial in Taizhou (Pyrotinib)

    Recruiting
    • Breast Cancer
    • Taizhou, Zhejiang, China
      Taizhou Hospital
    May 26, 2023

    Metastatic HER2-Positive Breast Cancer Trial in United States (Gemcitabine, Trastuzumab, Pertuzumab)

    Active, not recruiting
    • Metastatic HER2-Positive Breast Cancer
    • Hartford, Connecticut
    • +4 more
    Dec 1, 2022